Further examination of OS in the PALOMA-3, MONALEESA-3, MONALEESA-7, and MONARCH-2 studies further demonstrated that, in comparison to those receiving endocrine monotherapy, HR+/HER-2 advanced BC patients receiving CDK4/6 inhibitors in combination with ET also experienced considerably longer OS. Here, CDK4 is linked to breast cancer.